Benzinga | Nov 3, 2021 09:15AM EDT

Biocryst Pharmaceuticals Q3 EPS $(0.33) Misses $(0.29) Estimate, Sales $41.00M Beat $39.38M Estimate

Biocryst Pharmaceuticals (NASDAQ:BCRX) reported quarterly losses of $(0.33) per share which missed the analyst consensus estimate of $(0.29) by 13.79 percent. This is a 26.92 percent decrease over losses of $(0.26) per share from the same period last year. The company reported quarterly sales of $41.00 million which beat the analyst consensus estimate of $39.38 million by 4.11 percent. This is a 571.91 percent increase over sales of $6.10 million the same period last year.